NASDAQ:MRKR Marker Therapeutics - MRKR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.20 -0.56 (-31.82%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.11▼$1.7050-Day Range$0.33▼$3.1252-Week Range$1.11▼$6.60Volume262,222 shsAverage Volume46,498 shsMarket Capitalization$10.03 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Marker Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside25.0% Upside$1.50 Price TargetShort InterestHealthy0.90% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment-0.01Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector773rd out of 986 stocksPharmaceutical Preparations Industry370th out of 477 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $1.50, Marker Therapeutics has a forecasted upside of 25.0% from its current price of $1.20.Amount of Analyst CoverageMarker Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.90% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently increased by 64.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marker Therapeutics is -0.75. Previous Next 1.7 News and Social Media Coverage News SentimentMarker Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Marker Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for MRKR on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat Follows3 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.20% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.43% of the stock of Marker Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Marker Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marker Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Marker Therapeutics (NASDAQ:MRKR) StockMarker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.Read More Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRKR Stock News HeadlinesMarch 22, 2023 | benzinga.comMarker Therapeutics shares are trading lower after the company reported FY22 financial results.March 22, 2023 | seekingalpha.comMarker Therapeutics GAAP EPS of -$3.58 beats by $0.02, revenue of $9.01M beats by $0.01MMarch 22, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 22, 2023 | finance.yahoo.comMarker Therapeutics Reports Fiscal Year 2022 Corporate and Financial ResultsMarch 21, 2023 | marketwatch.comReport on Marker Equipment Market Size until 2026March 19, 2023 | marketwatch.comGlobal Cell Surface Marker Market 2023 Dynamics, Major Players, SWOT Analysis, and Business Forecast to 2030 By VMReportsMarch 19, 2023 | marketwatch.comGlobal Cardiac Marker Analyzer Market 2023 Recovering from Covid-19 Outbreak More Details About key players and Future Analysis 2030 By VMReportsMarch 18, 2023 | msn.comLake County to receive Bronze Marker honoring Revolutionary War veteransMarch 22, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 17, 2023 | marketwatch.comDNA Molecular Weight Marker Market Business Exploration in Brief with Important Statistics Forecast from 2023 to 2027March 17, 2023 | marketwatch.com2023 Side Marker Market: Thorough breakdown for industry leaders Prognosis by 2027March 14, 2023 | marketwatch.com2023-2029 Side Marker Lights Market Size, Gross Margin and Revenue Analysis | Research Report by Absolute ReportsMarch 13, 2023 | marketwatch.comWhite Board Marker Pen Market Insights-Industry changing aspects, New Technologies and Forecast to 2028March 12, 2023 | marketwatch.comGlobal Cardiac Marker Testing Market 2023 Outlook By Product, Application, And End-Use | Trends and Forecast To 2030 By VMReportsMarch 10, 2023 | marketwatch.comGlobal Protein Molecular Weight Marker Market Report 2023 by Trend, Potential and Forecasts Through 2030 By VMReportsMarch 9, 2023 | msn.comHow to get the Marker Cornbread in Find the Markers – RobloxMarch 9, 2023 | marketwatch.comWire Marker Card Market Growth Drivers, Technological Developments, Industry Overview, Forecast to 2029March 8, 2023 | msn.comHow to get the Poopy Blocky Marker in Find the Markers – RobloxMarch 8, 2023 | marketwatch.comTumor Marker Testing Market Size 2023 With Presentation Outlook, Horizontal Viewpoint, Global ViewMarch 7, 2023 | msn.comHow to get the Lucky Marker in Find the Markers – RobloxMarch 6, 2023 | msn.comHow to get the Clover Marker in Find the Markers – RobloxMarch 6, 2023 | msn.comHow to get the Cornbread Marker in Find the MarkersMarch 6, 2023 | msn.comHow to get the Lucky Marker in Find the MarkersMarch 5, 2023 | msn.comHow to get the Excalibur Marker in Find the MarkersMarch 4, 2023 | marketwatch.comMolecular Weight Marker Market Size PESTAL Analysis 2023 | Latest Survey Report by Absolute Reports till 2025March 3, 2023 | marketwatch.comGlobal DNA Molecular Weight Marker Market (2023-2028) Improving Ongoing Opportunities in Pharma and Healthcare Market | Research Reports WorldMarch 3, 2023 | marketwatch.comPortable Coffee Marker Market New Research Report with Future Growth and Development Forecast 2023-2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRKR Company Calendar Last Earnings11/10/2021Today3/22/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees56Year Founded2018Price Target and Rating Average Stock Price Forecast$1.50 High Stock Price Forecast$1.50 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+25.0%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($4.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,880,000.00 Net Margins-515.88% Pretax Margin-515.89% Return on Equity-110.00% Return on Assets-66.21% Debt Debt-to-Equity RatioN/A Current Ratio1.99 Quick Ratio1.99 Sales & Book Value Annual Sales$1.24 million Price / Sales8.09 Cash FlowN/A Price / Cash FlowN/A Book Value$5.29 per share Price / Book0.23Miscellaneous Outstanding Shares8,360,000Free Float6,086,000Market Cap$10.03 million OptionableOptionable Beta1.06 Social Links Key ExecutivesPeter L. HoangPresident, Chief Executive Officer & DirectorJuan F. VeraDirector, Chief Operating & Scientific OfficerTsvetelina Pencheva HoangVice President-Research & DevelopmentMythili KoneruChief Medical OfficerGerald GarrettVice President-Clinical OperationsKey CompetitorsCNS PharmaceuticalsNASDAQ:CNSPHumanigenNASDAQ:HGENBiofronteraNASDAQ:BFRIeFFECTOR TherapeuticsNASDAQ:EFTRInfinity PharmaceuticalsNASDAQ:INFIView All CompetitorsInstitutional OwnershipMillennium Management LLCBought 169,320 shares on 2/15/2023Ownership: 2.025%Renaissance Technologies LLCBought 11,700 shares on 2/13/2023Ownership: 1.952%Simplex Trading LLCBought 100 shares on 2/2/2023Ownership: 0.000%Matrix Asset Advisors Inc. NYSold 150,000 shares on 1/19/2023Ownership: 0.299%View All Institutional Transactions MRKR Stock - Frequently Asked Questions What is Marker Therapeutics' stock price forecast for 2023? 0 analysts have issued 1-year target prices for Marker Therapeutics' stock. Their MRKR share price forecasts range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View analysts price targets for MRKR or view top-rated stocks among Wall Street analysts. How have MRKR shares performed in 2023? Marker Therapeutics' stock was trading at $0.2659 on January 1st, 2023. Since then, MRKR shares have increased by 351.3% and is now trading at $1.20. View the best growth stocks for 2023 here. Are investors shorting Marker Therapeutics? Marker Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 65,400 shares, an increase of 64.3% from the February 13th total of 39,800 shares. Based on an average daily trading volume, of 38,500 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the shares of the company are sold short. View Marker Therapeutics' Short Interest. When is Marker Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our MRKR earnings forecast. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 110.00% and a negative net margin of 515.88%. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS). What is Marker Therapeutics' stock symbol? Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR." Who are Marker Therapeutics' major shareholders? Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.30%), Millennium Management LLC (2.03%), Renaissance Technologies LLC (1.95%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang. View institutional ownership trends. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Marker Therapeutics' stock price today? One share of MRKR stock can currently be purchased for approximately $1.20. How much money does Marker Therapeutics make? Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $10.03 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. How can I contact Marker Therapeutics? Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com. This page (NASDAQ:MRKR) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.